Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 02/07/2024

    Artificial intelligence helps physicians make precise heart diagnoses

    Researchers from the University of Heidelberg have published a study on more than 60,000 patients in the renowned journal Lancet Digital Health, demonstrating the potential of AI in cardiac medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-intelligence-helps-physicians-make-precise-heart-diagnoses
  • Press release - 02/07/2024

    Faster use of new technologies in rehabilitation

    BioRegio STERN Management GmbH is a partner in the new RehAllianCE project, which is being funded by the EU as part of the Interreg CENTRAL EUROPE program. The focus is on the use of new technologies in rehabilitation to improve patient care. The aim is to increase the innovation capacities of SMEs so that aids such as rehabilitation robots, exoskeletons etc. can be used more quickly.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/faster-use-new-technologies-rehabilitation
  • Press release - 24/06/2024

    Digital babies created to improve infant healthcare

    Researchers at University of Galway, the Heidelberg Institute for Theoretical Studies (HITS) Heidelberg University, and Heidelberg University Hospital have created digital babies to better understand infants’ health in their critical first 180 days of life. The international team created computer models that simulate the unique metabolic processes of each baby. The models can help to better understand rare metabolic diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-babies-created-improve-infant-healthcare
  • Press release - 21/06/2024

    New tool maps microbial diversity with unprecedented details

    Researchers from the Max Planck Institute for Biology Tübingen developed the groundbreaking tool SynTracker. SynTracker expands traditional microbial analysis by considering genomic structural variation to complement existing SNP-based methods. This innovation reveals more precision and depths of microbial strain diversity and evolution.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-tool-maps-microbial-diversity-unprecedented-details
  • Gender-specific differences - 18/06/2024 Gendermedizin_Portrait_Prof._Loges_Teaser.jpg

    Gender medicine: Why is good healthcare not a matter of course for everyone?

    Gender medicine is the study of gender-specific health differences. Many diseases manifest themselves differently in men and women and therapies do not always have the same effect depending on the sex of the patient being treated. There is currently not enough data on these differences. Research teams including the one led by Professor Dr. Dr. Sonja Loges from the University Medical Centre Mannheim and the DKFZ are seeking to change this.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gender-medicine-why-good-healthcare-not-matter-course-everyone
  • Press release - 13/06/2024

    Which of the two DNA strands is damaged influences the cell's mutation profile

    Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/which-two-dna-strands-damaged-influences-cells-mutation-profile
  • Press release - 13/06/2024

    Position of the cell nucleus affects epigenetics and therefore gene activity and cell function

    Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/position-cell-nucleus-affects-epigenetics-and-therefore-gene-activity-and-cell-function
  • Press release - 12/06/2024

    Pathogen identification — next-generation sequencing optimizes diagnostics

    Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pathogen-identification-next-generation-sequencing-optimizes-diagnostics
  • Press release - 07/06/2024

    German Research Foundation honors researchers for animal testing alternatives

    Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-research-foundation-honors-researchers-animal-testing-alternatives
  • Press release - 31/05/2024

    Heidelberg University successful with six bids for collaborative research

    In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-university-successful-six-bids-collaborative-research
  • Press release - 23/05/2024

    Predicting cancer risks on the basis of national health data

    Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/predicting-cancer-risks-basis-national-health-data
  • Press release - 22/05/2024

    Stretched beyond the limits of the cell: the molecular biomechanics of collagen

    Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/stretched-beyond-limits-cell-molecular-biomechanics-collagen
  • Press release - 16/05/2024

    Colorectal cancer: tracking down subtypes

    Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-tracking-down-subtypes
  • Press release - 07/05/2024

    Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects

    Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
  • Press release - 06/05/2024

    Research under high pressure

    Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-under-high-pressure
  • Press release - 03/05/2024

    Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

    Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies
  • Press release - 24/04/2024

    CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

    Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
  • Press release - 17/04/2024

    Cell Biology: Molecular Code Stimulates Pioneer Cells to Build Blood Vessels in the Body

    Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zellbiologie-molekularer-code-regt-pionierzellen-zum-aufbau-von-blutgefaessen-im-koerper
  • Press release - 11/04/2024

    How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation

    Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft
  • Press release - 27/03/2024

    Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

    Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
  • Press release - 22/03/2024

    Decoding the shared genetic toolkit for male sex determination

    Researchers from the Max Planck Institute for Biology Tübingen broke new ground by demonstrating that an HMG-box gene in brown algae is crucial for determining male sex. This breakthrough significantly expands our understanding of sex-determination mechanisms in eukaryotic organisms. Until now, master sex-determination genes had been identified in only a select number of animals and plants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/decoding-shared-genetic-toolkit-male-sex-determination
  • Press release - 22/03/2024

    New Emmy Noether junior research group for biological data science

    An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
  • Press release - 14/03/2024

    Machine learning classifier accelerates the development of cellular immunotherapies

    Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-classifier-accelerates-development-cellular-immunotherapies
  • Press release - 14/03/2024

    Next milestone in the treatment of liver tumors and acute and chronic liver diseases

    The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
  • Stem cell research - 14/03/2024 Image of red and blue coloured, round structures.

    Using organoids to gain a better clinical understanding of pancreatic cancer

    Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
  • Press release - 13/03/2024

    Diabetes: New technology opens up improved opportunities for research

    More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-new-technology-opens-improved-opportunities-research
  • Press release - 13/03/2024

    Protection from an unexpected source

    Contrary to common belief, not all viruses are harmful to their hosts. Sometimes viruses can even protect their hosts from infection by other viruses. Scientists at the Max-Planck-Institute for Medical Research in Heidelberg and their collaborators have now demonstrated that this is the case for so-called endogenous virophages: small DNA viruses that are mostly found inserted into the genomes of single-cell eukaryotes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/protection-unexpected-source
  • Press release - 05/03/2024

    New Center for Synthetic Genomics

    Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
  • Press release - 04/03/2024

    First Step Toward Early Diagnosis of Metastasis

    Team involving the University of Freiburg has developed a new analytical method for the basement membrane in human lungs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-step-toward-early-diagnosis-metastasis
  • Press release - 04/03/2024

    Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

    HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million
  • Press release - 01/03/2024

    Using Data to Improve Understanding of Relationships between Proteins and Diseases

    Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
  • Neurosciences - 28/02/2024 A microscopic image shows how a brain organoid grows around and through the mesh microelectrode array.

    Mesh microelectrode arrays: research with brain organoids on a new level

    How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mesh-microelectrode-arrays-research-brain-organoids-new-level
  • Press release - 22/02/2024

    A new approach to recording cellular activities

    In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities
  • Press release - 15/02/2024

    Modelling the spread of diseases

    Computer scientists from the Cluster of Excellence Collective Behaviour developed a model, that explains how collective scenarios such as diseases may proceed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/modelling-spread-diseases
  • Press release - 07/02/2024

    The unexpected long-term consequences of female fertility

    The constant remodeling of the organs of the female reproductive tract during the reproductive cycle leads to fibrosis and chronic inflammation over the years. Scientists from the German Cancer Research Center (DKFZ) have now uncovered these unexpected long-term consequences of female reproductive function in mice. The results have been published in the scientific journal CELL.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/die-unerwartete-auswirkung-der-weiblichen-fortpflanzungsfaehigkeit
  • Press release - 06/02/2024

    New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

    BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-t-finder-plattform-liefert-tiefe-einblicke-t-zell-antwort-auf-neuartigen-krebsimpfstoff
  • Press release - 02/02/2024

    Epigenetic status determines metastasis

    Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung
  • Press release - 31/01/2024

    Precursor of Cholesterol Protects Cancer Cells From Cell Death and Makes them Aggressive

    A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cholesterin-vorstufe-schuetzt-krebszellen-vor-zelltod-und-macht-sie-aggressiver
  • Press release - 17/01/2024

    AI-based support system for skin cancer diagnostics explains its decisions

    Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions
  • Press release - 15/01/2024

    Maturation instead of cell death: Defective signalling pathways disrupt immune cell development

    Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.

    https://www.gesundheitsindustrie-bw.de/en/article/maturation-instead-cell-death-defective-signalling-pathways-disrupt-immune-cell-development
  • Health Data Futures project - 11/01/2024 Eine runde Darstellung der verschiedenen Szenario-Cluster, bei denen farblich markierten Szenarien in den Clustern herausgearbeitet wurden.

    Creating a network of trust

    In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.

    https://www.gesundheitsindustrie-bw.de/en/article/news/creating-network-trust
  • Press release - 08/01/2024

    Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor

    Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
  • Press release - 05/01/2024

    Prostate cancer: Newly-developed inhibitor shows massive potential

    More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
  • Press release - 05/01/2024

    How memories are formed in the brain – a new role for the internal compass

    University of Tübingen neuroscientists discover new functions of head-direction cells suggesting they may contribute to episodic memory formation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-memories-are-formed-brain-new-role-internal-compass
  • Press release - 04/01/2024

    Key player in viral heart inflammation discovered

    Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered
  • Press release - 18/12/2023

    Researchers discover novel antibiotic substance from the human nose

    For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose
  • Press release - 08/12/2023

    Where does chronic pain come from?

    Professor Dr. Rohini Kuner from the Medical Faculty of Heidelberg University receives the Leibniz Prize of the German Research Foundation (DFG).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/woher-kommen-chronische-schmerzen
  • Press release - 30/11/2023

    Taking antibiotics back in time

    University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/taking-antibiotics-back-time
  • Press release - 29/11/2023

    Tracing the Evolution of the Cerebellum

    Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum
  • Press release - 15/11/2023

    Nanoparticles for optimized cancer therapy

    Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanopartikel-fuer-optimierte-krebstherapie
  • Press release - 10/11/2023

    Therapy resistance in multiple myeloma: molecular analyses of individual cancer cells reveal new mechanisms

    All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapy-resistance-multiple-myeloma-molecular-analyses-individual-cancer-cells-reveal-new-mechanisms
  • Press release - 06/11/2023

    Improving the efficacy of cancer immunotherapy with modified CAR-T cells

    CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
  • Press release - 30/10/2023

    New research group: construction of tissue in laboratory

    An interdisciplinary research group combining mechanical engineering and biotechnology has taken up its work at the Institute for Molecular Systems Engineering and Advanced Materials (IMSEAM) of Heidelberg University. The team under the direction of Dr Kai Melde will pursue an innovative approach to biofabrication – 3D cell culture using ultrasound. Tools are being developed that can be used as an alternative to or enhancement for 3D printing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-forschungsgruppe-konstruktion-von-gewebe-im-labor
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
  • Press release - 20/10/2023

    Why tuberculosis bacteria form long chains

    A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have now been published in the journal Cell.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-tuberculosis-bacteria-form-long-chains
  • Press release - 04/10/2023

    Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion

    A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
  • Press release - 21/09/2023

    Mutation-specific peptide vaccine against midline gliomas used in patients for the first time

    Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time
  • Press release - 19/09/2023

    Better distinguish chronic inflammation and cancer of the pancreas

    Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
  • Press release - 28/08/2023

    Innovative computational approach helps design proteins for cancer treatment

    The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
  • Press release - 10/08/2023

    Computer-aided cell analysis for faster diagnosis of blood diseases

    Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/computergestuetzte-zellanalyse-fuer-die-schnellere-diagnose-von-blutkrankheiten
  • Press release - 07/08/2023

    Vegan trend in Europe: In Germany, milk substitutes from plants are most popular alternative

    Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vegan-trend-europe-germany-milk-substitutes-plants-are-most-popular-alternative
  • Press release - 02/08/2023

    Freiburg research team casts light on signal-dependent formation of mitochondria

    Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
  • Press release - 20/07/2023

    Animal testing under REACH: bringing numbers into the debate

    So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tierversuche-durch-reach-zahlen-die-debatte-bringen
  • Press release - 20/07/2023

    Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention

    A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/anal-cancer-screening-new-microbiome-associated-biomarkers-could-improve-prevention
  • Press release - 13/07/2023

    Intelligent rubber materials

    Wearable medical devices, such as soft exoskeletons that provide support for stroke patients or controlled drug delivery patches, have to be made of materials that can adapt intelligently and autonomously to the wearer's movements and to changing environmental conditions. These are the type of autonomously switchable polymer materials that have recently been developed by researchers at the University of Stuttgart and the University of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/intelligent-rubber-materials
  • Press release - 12/07/2023

    Mast cells as a sensor: Enigmatic immune cells help to avoid harmful allergens

    The function of mast cells, which are part of the immune system, is still a mystery. Scientists at the German Cancer Research Center (DKFZ) have now shown in mice: mast cells function as a sensor that signals the animals to avoid antigens, including harmful allergens, and thereby protect themselves from health-threatening inflammatory reactions. The findings were published in the journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mastzellen-als-sensor-raetselhafte-immunzellen-helfen-schaedliche-allergene-zu-vermeiden
  • Press release - 23/06/2023

    The molecular control centre of our protein factories

    Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
  • Press release - 20/06/2023

    CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

    CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma. A first data readout is expected in the second half of 2024.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-patient-phase-1-study-cancer-vaccine-candidate-surgically-resected-glioblastoma
  • Press release - 16/06/2023

    What determines whether breast cancer cells can form metastases?

    In most cancers, it is not the growth of the primary tumor that determines the prognosis for the patient, but whether it will spread and form metastases. This process is very complex. There are often years between the development of the cancer and the aggressive growth of the metastases. Scientists from the DKFZ, the HI-STEM, the Ruhr University Bochum, Helmholtz Munich and ETH Zurich have studied and identified metastasis growth in breast cancer

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-determines-whether-breast-cancer-cells-can-form-metastases
  • Press release - 05/06/2023

    New findings about human metabolic processes

    Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes
  • Press release - 25/05/2023

    Oops, did I do that – or is there someone else in my head?

    Tübingen researchers describe connection between action and feeling of authorship - finding sheds light on delusions of external control in schizophrenia

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/oops-did-i-do-or-there-someone-else-my-head
  • Press release - 24/05/2023

    Epigenetic profiling identifies potential COPD treatment targets

    Impaired function of lung fibroblast is considered causative for symptoms of the incurable lung disease COPD (Chronic Obstructive Pulmonary Disease). Using high-resolution epigenetic profiling, German and British scientists have now identified potential targets for COPD treatment. The team detected early epigenetic changes in the genome of COPD fibroblasts, providing new insights into the disease pathogenesis and potential therapeutic avenues.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-profiling-identifies-potential-copd-treatment-targets
  • Press release - 23/05/2023

    B cells promote liver cancer with dangerous dual strategy

    Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/b-cells-promote-liver-cancer-dangerous-dual-strategy
  • Press release - 22/05/2023

    Prevention of pandemics

    Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-pandemics

Page 2 / 5

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search